RxDoctor Payments Data

Semira Charboneau, DO

Internal Medicine · Ada, OKNPI 1619975745

Payments from drug & device makers

$271in general payments, 2019–2025

Across 15 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$47
  • Novo Nordisk$37
  • AstraZeneca$33
  • Sumitomo Pharma America, Inc.$29
  • AbbVie$26
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$21
  • plus $78 from 5 others

What the payments were for

  • Food & beverage$271100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$271 in reported general payments places this provider in the 50th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$9,299
Medicare patients
217
Services billed
662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$111,821
EliquisApixaban73$70,318
JardianceEmpagliflozin46$67,654
TrulicityDulaglutide60$63,986
FarxigaDapagliflozin Propanediol34$50,792
MounjaroTirzepatide37$42,856
JanuviaSitagliptin Phosphate16$21,110
Dexlansoprazole DrDexlansoprazole38$13,795
XareltoRivaroxaban14$12,757
MyrbetriqMirabegron16$10,369
Tresiba Flextouch U-200Insulin Degludec15$8,682
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,618
Ondansetron Hcl23$7,497
Breo ElliptaFluticasone/Vilanterol11$4,953
Rosuvastatin Calcium116$4,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$37$111,821107 claims
Lilly USA, LLCTrulicity, Mounjaro$15$106,84297 claims
PfizerEliquis$47$70,31873 claims
Boehringer IngelheimJardiance$13$67,65446 claims
AstraZenecaFarxiga, Breztri Aerosphere$33$59,41048 claims
GSKBreo Ellipta$14$4,95311 claims
AbbVieSynthroid$26$1,59121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Ada

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →